Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects
Luminal HER2-negative subtypes of breast cancer have always attracted oncologists due to their sensitivity to low-toxicity hormone therapy. The emergence of new inhibitors of cyclin-dependent kinases has allowed hormone therapy to achieve optimal control of tumor growth, being prescribed even for vi...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2025-07-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/3199 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240754805800960 |
|---|---|
| author | A. V. Sultanbaev I. A. Tuzankina I. V. Kolyadina A. F. Nasretdinov Sh. I. Musin N. I. Sultanbaeva K. V. Menshikov A. A. Izmailov M. V. Sultanbaev D. A. Kudlay |
| author_facet | A. V. Sultanbaev I. A. Tuzankina I. V. Kolyadina A. F. Nasretdinov Sh. I. Musin N. I. Sultanbaeva K. V. Menshikov A. A. Izmailov M. V. Sultanbaev D. A. Kudlay |
| author_sort | A. V. Sultanbaev |
| collection | DOAJ |
| description | Luminal HER2-negative subtypes of breast cancer have always attracted oncologists due to their sensitivity to low-toxicity hormone therapy. The emergence of new inhibitors of cyclin-dependent kinases has allowed hormone therapy to achieve optimal control of tumor growth, being prescribed even for visceral lesions. Recent advances in this area have provided novel mode of hormonal therapy as the first-line standard for extended HR+/HER2- breast cancer. Evaluation of the relationship between tumor progression and immune surveillance was more often associated with the triple-negative subtype characterized by relatively high levels of mutational load and tumor-infiltrating lymphocytes. However, data from some studies suggest a possible relationship between immunity and luminal types of breast cancer. On the basis of these conclusions, the aim of our work was to evaluate different immunological and clinical factors in view of effectiveness of combined endocrine therapy with CDK4/6 inhibitors in metastatic luminal HR+/HER2- breast cancer, primarily in the context of assessing immune deficiency conditions by the levels of T-cell receptor excision circles (TREC) and κ-deletion element of B cells (KREC). The study included 51 patients with luminal HER2-negative breast cancer who received combined endocrine therapy with CDK4/6 inhibitors. The results of the study indicated a decrease in TREC levels with increasing patients’ age. A decrease in the absolute number of TREC was noted in peripheral blood of patients with worse treatment outcomes, i.e., insufficient response to therapy, rapid progression or death, along with significant intercorrelation between lethal outcomes and low levels of B cell κ-deletion element (KREC) thus suggesting an important role of these immune factors in clinical prognosis. Hence, we consider prognostic significance of T cell receptor excision rings in the patients’ peripheral blood. This factor may affect treatment outcomes and survival rates. |
| format | Article |
| id | doaj-art-be7994ca3e364cea8c3d5d39ea9fa6a3 |
| institution | Kabale University |
| issn | 1563-0625 2313-741X |
| language | Russian |
| publishDate | 2025-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj-art-be7994ca3e364cea8c3d5d39ea9fa6a32025-08-20T04:00:27ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2025-07-0127474976010.15789/1563-0625-EOC-31992007Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspectsA. V. Sultanbaev0I. A. Tuzankina1I. V. Kolyadina2A. F. Nasretdinov3Sh. I. Musin4N. I. Sultanbaeva5K. V. Menshikov6A. A. Izmailov7M. V. Sultanbaev8D. A. Kudlay9Republican Clinical Oncology Dispensary; Bashkir State Medical University; Republican Medical Genetic Center of Republic of BashkortostanInstitute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; Sverdlovsk Region Regional Pediatric Clinical HospitalRussian Medical Academy of Continuous Professional Education; V. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology National Medical Research Center for Obstetrics, Gynecology, and Perinatology named after Academician V.I. KulakovRepublican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryRepublican Clinical Oncology Dispensary; Bashkir State Medical University; Republican Medical Genetic Center of Republic of BashkortostanRepublican Clinical Oncology DispensaryBashkir State Medical UniversityI. Sechenov First Moscow State Medical University (Sechenov University); i State Research Center “Institute of Immunology” of the Federal Medical and Biological Agency; Lomonosov Moscow State UniversityLuminal HER2-negative subtypes of breast cancer have always attracted oncologists due to their sensitivity to low-toxicity hormone therapy. The emergence of new inhibitors of cyclin-dependent kinases has allowed hormone therapy to achieve optimal control of tumor growth, being prescribed even for visceral lesions. Recent advances in this area have provided novel mode of hormonal therapy as the first-line standard for extended HR+/HER2- breast cancer. Evaluation of the relationship between tumor progression and immune surveillance was more often associated with the triple-negative subtype characterized by relatively high levels of mutational load and tumor-infiltrating lymphocytes. However, data from some studies suggest a possible relationship between immunity and luminal types of breast cancer. On the basis of these conclusions, the aim of our work was to evaluate different immunological and clinical factors in view of effectiveness of combined endocrine therapy with CDK4/6 inhibitors in metastatic luminal HR+/HER2- breast cancer, primarily in the context of assessing immune deficiency conditions by the levels of T-cell receptor excision circles (TREC) and κ-deletion element of B cells (KREC). The study included 51 patients with luminal HER2-negative breast cancer who received combined endocrine therapy with CDK4/6 inhibitors. The results of the study indicated a decrease in TREC levels with increasing patients’ age. A decrease in the absolute number of TREC was noted in peripheral blood of patients with worse treatment outcomes, i.e., insufficient response to therapy, rapid progression or death, along with significant intercorrelation between lethal outcomes and low levels of B cell κ-deletion element (KREC) thus suggesting an important role of these immune factors in clinical prognosis. Hence, we consider prognostic significance of T cell receptor excision rings in the patients’ peripheral blood. This factor may affect treatment outcomes and survival rates.https://www.mimmun.ru/mimmun/article/view/3199hr<sup>+</sup>/her2<sup>-</sup> breast cancercdk4/6 inhibitorsendocrinotherapyantitumor immunitytreckrec |
| spellingShingle | A. V. Sultanbaev I. A. Tuzankina I. V. Kolyadina A. F. Nasretdinov Sh. I. Musin N. I. Sultanbaeva K. V. Menshikov A. A. Izmailov M. V. Sultanbaev D. A. Kudlay Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects Медицинская иммунология hr<sup>+</sup>/her2<sup>-</sup> breast cancer cdk4/6 inhibitors endocrinotherapy antitumor immunity trec krec |
| title | Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects |
| title_full | Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects |
| title_fullStr | Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects |
| title_full_unstemmed | Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects |
| title_short | Efficiency of combined endocrine therapy with CDK4/6 inhibitors in metastatic HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: Immunological aspects |
| title_sort | efficiency of combined endocrine therapy with cdk4 6 inhibitors in metastatic hr sup sup her2 sup sup breast cancer immunological aspects |
| topic | hr<sup>+</sup>/her2<sup>-</sup> breast cancer cdk4/6 inhibitors endocrinotherapy antitumor immunity trec krec |
| url | https://www.mimmun.ru/mimmun/article/view/3199 |
| work_keys_str_mv | AT avsultanbaev efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT iatuzankina efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT ivkolyadina efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT afnasretdinov efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT shimusin efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT nisultanbaeva efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT kvmenshikov efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT aaizmailov efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT mvsultanbaev efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects AT dakudlay efficiencyofcombinedendocrinetherapywithcdk46inhibitorsinmetastatichrsupsupher2supsupbreastcancerimmunologicalaspects |